newsfilter
← Latest News
GlobeNewswire·

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 DRAGON trial Company